ARID4B's role in estrogen-positive breast cancer
Molecular Function and Mechanism of ARID4B in ERalpha Signaling and Breast Cancer
This project looks at whether the protein ARID4B helps drive estrogen-receptor positive breast cancers and contributes to resistance to hormone therapy, with the aim of helping patients whose tumors stop responding to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11143658 on NIH RePORTER |
What this research studies
Researchers are examining how ARID4B interacts with the estrogen receptor to turn on cancer-promoting genes by combining analyses of tumor data, tissue staining, and lab experiments. They will analyze large genomic datasets (like TCGA) and measure ARID4B levels in patient tumor samples using IHC. In the lab they will manipulate ARID4B in breast cancer cells and mouse models to see how loss or gain of ARID4B changes tumor growth and response to endocrine therapies. Findings may point to markers or molecular targets that could guide future treatments for patients with resistant ER-positive breast cancer.
Who could benefit from this research
Good fit: People with estrogen receptor–positive (ER+) breast cancer, especially those with advanced or metastatic disease that is resistant to endocrine therapy, are the most relevant group for this research.
Not a fit: Patients with estrogen receptor–negative breast cancers or unrelated diseases would be unlikely to benefit directly from this specific project.
Why it matters
Potential benefit: If successful, this work could identify new targets or tests to help prevent or overcome hormone therapy resistance in ER-positive breast cancer.
How similar studies have performed: Other studies have linked chromatin regulators to hormone resistance in breast cancer, but ARID4B is a newer target with promising early data that has not yet been validated in patients.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Wu, Ray-Chang — George Washington University
- Study coordinator: Wu, Ray-Chang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.